Angioimmunoblastic T-cell lymphoma

2 trials MedDRA PT
2 Registered trials
0 Recruiting
2 Unique sponsors
1 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 1 substance
Phase I/II: 1 Phase I: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase I/II

1 trial
  • Fondazione Italiana Linfomi Ets Academic
    ROMIDEPSIN
    2024-511639-83-00 1 country 2014 n=125 Orphan
    Ended

Phase I

1 trial
  • Seagen Inc. Commercial
    IMP not specified
    2022-502390-41-00 4 countries 2024 n=35
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Seagen Inc. Commercial 1 Phase I 0
Fondazione Italiana Linfomi Ets Academic 1 Phase I/II 0
New trials by year
2024
1
← All indication landscapes